The incidence of vasculitides in Israel from 2007 to 2021 and during the COVID-19 pandemic.

IF 3.4 2区医学 Q2 RHEUMATOLOGY

Therapeutic Advances in Musculoskeletal Disease Pub Date : 2024-10-07 eCollection Date: 2024-01-01 DOI:10.1177/1759720X241274032

Lior Zeller, Ran Ben David, Lena Novack, Ran Abuhasira, Mahmoud Abu-Shakra, Yuval Miskin, Iftach Sagy

{"title":"The incidence of vasculitides in Israel from 2007 to 2021 and during the COVID-19 pandemic.","authors":"Lior Zeller, Ran Ben David, Lena Novack, Ran Abuhasira, Mahmoud Abu-Shakra, Yuval Miskin, Iftach Sagy","doi":"10.1177/1759720X241274032","DOIUrl":null,"url":null,"abstract":"Background: The incidence of various types of vasculitis conditions over time, specifically during coronavirus disease 2019 (COVID-19), is unknown.Objectives: We aimed to assess recent trends in vasculitides and the effect of the COVID-19 pandemic on these trends.Design: We conducted a retrospective analysis of Israel's largest Health Maintenance Organization, which covers over 4.7 million patients and represents 55% of the country.Methods: We calculated the age- and sex-adjusted incidence of giant cell arteritis (GCA), Takayasu, ANCA-associated vasculitis (AAV), IgA vasculitis, cryoglobulinemia, and Behcet's disease (BD) during 2007-2021. We analyzed associations of COVID-19 with the incidence of each of the examined conditions.Results: During 2007-2021, the adjusted annual incidence decreased from 7.9 (95% confidence interval (CI) 3.5-17.9) to 1.5 (95% CI 0.7-3.6) per 100,000 for GCA, from 5.2 (95% CI 2.7-11.1) to 1.5 (95% CI 0.7-3.3) per million for IgA vasculitis, and from 6.3 (95% CI 3.0-13.5) to 1.0 (0.5-2.5) per 100,000 for BD. The relative risks for these conditions decreased: 0.92 (95% CI 0.91-0.93), 0.93 (95% CI 0.89-0.98), and 0.90 (95% CI 0.85-0.94), respectively. The incidences of Takayasu, AAV, and cryoglobulinemia remained unchanged. The COVID-19 pandemic was not associated with changes in the incidence of any examined vasculitides.Conclusion: The incidences of GCA, IgA vasculitis, and BD decreased substantially in Israel during 15 years and were unaffected by the COVID-19 pandemic. Future studies should focus on possible environmental contributions to these findings.","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"16 ","pages":"1759720X241274032"},"PeriodicalIF":3.4000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465294/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Musculoskeletal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1759720X241274032","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The incidence of various types of vasculitis conditions over time, specifically during coronavirus disease 2019 (COVID-19), is unknown.

Objectives: We aimed to assess recent trends in vasculitides and the effect of the COVID-19 pandemic on these trends.

Design: We conducted a retrospective analysis of Israel's largest Health Maintenance Organization, which covers over 4.7 million patients and represents 55% of the country.

Methods: We calculated the age- and sex-adjusted incidence of giant cell arteritis (GCA), Takayasu, ANCA-associated vasculitis (AAV), IgA vasculitis, cryoglobulinemia, and Behcet's disease (BD) during 2007-2021. We analyzed associations of COVID-19 with the incidence of each of the examined conditions.

Results: During 2007-2021, the adjusted annual incidence decreased from 7.9 (95% confidence interval (CI) 3.5-17.9) to 1.5 (95% CI 0.7-3.6) per 100,000 for GCA, from 5.2 (95% CI 2.7-11.1) to 1.5 (95% CI 0.7-3.3) per million for IgA vasculitis, and from 6.3 (95% CI 3.0-13.5) to 1.0 (0.5-2.5) per 100,000 for BD. The relative risks for these conditions decreased: 0.92 (95% CI 0.91-0.93), 0.93 (95% CI 0.89-0.98), and 0.90 (95% CI 0.85-0.94), respectively. The incidences of Takayasu, AAV, and cryoglobulinemia remained unchanged. The COVID-19 pandemic was not associated with changes in the incidence of any examined vasculitides.

Conclusion: The incidences of GCA, IgA vasculitis, and BD decreased substantially in Israel during 15 years and were unaffected by the COVID-19 pandemic. Future studies should focus on possible environmental contributions to these findings.

查看原文本刊更多论文

2007 年至 2021 年以及 COVID-19 大流行期间以色列血管病的发病率。

背景：各种类型的血管炎病症随着时间推移的发病率，特别是在2019年冠状病毒疾病（COVID-19）期间的发病率尚不清楚：我们旨在评估血管炎的近期趋势以及 COVID-19 大流行对这些趋势的影响：我们对以色列最大的健康维护组织进行了回顾性分析，该组织覆盖了 470 多万名患者，占全国人口的 55%：我们计算了 2007-2021 年期间巨细胞动脉炎 (GCA)、Takayasu、ANCA 相关性血管炎 (AAV)、IgA 血管炎、冷球蛋白血症和白塞氏病 (BD) 的年龄和性别调整后发病率。我们分析了 COVID-19 与每种受检疾病发病率的关系：结果：2007-2021年间，GCA的调整后年发病率从每100,000人7.9例（95%置信区间（CI）3.5-17.9例）下降到1.5例（95% CI 0.7-3.6例），IgA血管炎从每100万人5.2例（95% CI 2.7-11.1例）下降到1.5例（95% CI 0.7-3.3例），BD从每100,000人6.3例（95% CI 3.0-13.5例）下降到1.0例（0.5-2.5例）。这些疾病的相对风险均有所下降：分别为 0.92（95% CI 0.91-0.93）、0.93（95% CI 0.89-0.98）和 0.90（95% CI 0.85-0.94）。高安症、AAV 和低温球蛋白血症的发病率保持不变。COVID-19大流行与任何受检血管性疾病的发病率变化无关：结论：15 年间，以色列的 GCA、IgA 血管炎和 BD 发病率大幅下降，且不受 COVID-19 大流行的影响。未来的研究应重点关注环境对这些发现可能造成的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Musculoskeletal Disease Medicine-Rheumatology

CiteScore

6.80

自引率

4.80%

发文量

132

审稿时长

18 weeks

期刊介绍： Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of musculoskeletal disease.